Dose-response relationship for breast cancer induction at radiotherapy dose

Radiation Oncology

Jürgen Besserer¹  Andreas Mack¹  Günther Gruber¹  Judith Robotka¹  Marcin Sumila¹  Uwe Schneider¹ 

[1] Institute for Radiotherapy, Hirslanden Hospital Zürich, Witellikerstrasse 40, 8032 Zürich, Switzerland

关键词: carcinogenesis;    breast cancer;    second cancer;   

Others  :  1224342
DOI  :  10.1186/1748-717X-6-67

 received in 2011-03-23, accepted in 2011-06-08,  发布年份 2011

【 摘 要 】

Purpose

Cancer induction after radiation therapy is known as a severe side effect. It is therefore of interest to predict the probability of second cancer appearance for the patient to be treated including breast cancer.

Materials and methods

In this work a dose-response relationship for breast cancer is derived based on

(i) the analysis of breast cancer induction after Hodgkin's disease,

(ii) a cancer risk model developed for high doses including fractionation based on the linear quadratic model, and

(iii) the reconstruction of treatment plans for Hodgkin's patients treated with radiotherapy,

(iv) the breast cancer induction of the A-bomb survivor data.

Results

The fitted model parameters for an α/β = 3 Gy were α = 0.067Gy^-1 and R = 0.62. The risk for breast cancer is according to this model for small doses consistent with the finding of the A-bomb survivors, has a maximum at doses of around 20 Gy and drops off only slightly at larger doses. The predicted EAR for breast cancer after radiotherapy of Hodgkin's disease is 11.7/10000PY which can be compared to the findings of several epidemiological studies where EAR for breast cancer varies between 10.5 and 29.4/10000PY. The model was used to predict the impact of the reduction of radiation volume on breast cancer risk. It was estimated that mantle field irradiation is associated with a 3.2-fold increased risk compared with mediastinal irradiation alone, which is in agreement with a published value of 2.7. It was also shown that the modelled age dependency of breast cancer risk is in satisfying agreement with published data.

Conclusions

The dose-response relationship obtained in this report can be used for the prediction of radiation induced secondary breast cancer of radiotherapy patients.

【 授权许可】

   
2011 Schneider et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Schneider U, Zwahlen D, Ross D, et al.: Estimation of radiation-induced cancer from three-dimensional dose distributions: Concept of organ equivalent dose. Int J Radiat Oncol Biol Phys 2005, 61(5):1510-5.
• [2]Sachs RK, Brenner DJ: Solid tumor risks after high doses of ionizing radiation. Proc Natl Acad Sci USA 2005, 102(37):13040-5. 13
• [3]Schneider U, Stipper A, Besserer J: Dose-response relationship for lung cancer induction at radiotherapy dose. Z Med Phys 2010, 20(3):206-14.
• [4]Dörr W, Herrmann T: Second primary tumors after radiotherapy for malignancies. Treatment-related parameters. Strahlenther Onkol 2002, 178(7):357-62.
• [5]Travis LB, Gospodarowicz M, Curtis RE, et al.: Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst 2002, 94(3):182-92.
• [6]Gilbert ES, Stovall M, Gospodarowicz M, et al.: Lung cancer after treatment for Hodgkin's disease: focus on radiation effects. Radiat Res 2003, 159(2):161-73.
• [7]Diallo I, Haddy N, Adjadj E, et al.: Frequency distribution of second solid cancer locations in relation to the irradiated volume among 115 patients treated for childhood cancer. Int J Radiat Oncol Biol Phys 2009, 74(3):876-83.
• [8]Travis LB, Hill DA, Dores GM, et al.: Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA 2003, 290(4):465-75.
• [9]van Leeuwen FE, Klokman WJ, Stovall M, et al.: Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst 2003, 95(13):971-80.
• [10]Inskip PD, Robison LL, Stovall M, Smith SA, Hammond S, Mertens AC, Whitton JA, Diller L, Kenney L, Donaldson SS, Meadows AT, Neglia JP: Radiation dose and breast cancer risk in the childhood cancer survivor study. J Clin Oncol 2009, 27(24):3901-7.
• [11]Preston DL, Ron E, Tokuoka S, et al.: Solid cancer incidence in atomic bomb survivors: 1958-1998. Radiat Res 2007, 168(1):1-64.
• [12]Schneider U: Mechanistic model of radiation-induced cancer after fractionated radiotherapy using the linear-quadratic formula. Med Phys 2009, 36(4):1138-43.
• [13]Hoppe RT: Radiation therapy in the management of Hodgkin's disease. Semin Oncol 1990, 17(6):704-15.
• [14]Hancock SL, Hoppe RT: Long-Term Complications of Treatment and Causes of Mortality After Hodgkin's Disease. Semin Radiat Oncol 1996, 6(3):225-242.
• [15]Swerdlow AJ, Barber JA, Hudson GV, et al.: Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol 2000, 18(3):498-509.
• [16]Dores GM, Metayer C, Curtis RE, et al.: Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. J Clin Oncol 2002, 20(16):3484-94.
• [17]van Leeuwen FE, Klokman WJ, Veer MB, et al.: Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. J Clin Oncol 2000, 18(3):487-97.
• [18]De Bruin ML, Sparidans J, van't Veer MB, et al.: Breast cancer risk in female survivors of Hodgkin's lymphoma: lower risk after smaller radiation volumes. J Clin Oncol 2009, 27(26):4239-46. 10
• [19]Koh ES, Tran TH, Heydarian M, Sachs RK, Tsang RW, Brenner DJ, Pintilie M, Xu T, Chung J, Paul N, Hodgson DC: A comparison of mantle versus involved-field radiotherapy for Hodgkin's lymphoma: reduction in normal tissue dose and second cancer risk. Radiat Oncol 2007, 2:13. BioMed Central Full Text